OKYO Pharma Announces New Analyses Of Corneal Images From Placebo-Controlled, Randomized, Double-Masked, Phase 2 Clinical Trial Of Urcosimod In Neuropathic Corneal Pain

• Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo group
• These findings suggest that urcosimod may have a positive impact on corneal nerve health in patients with neuropathic corneal pain
• Corneal nerve imaging data from the Phase 2 NCP trial were analyzed using in vivo confocal microscopy

LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce new analyses of corneal images from the recently completed placebo-controlled, randomized, double-masked, Phase 2 clinical trial of urcosimod in neuropathic corneal pain (NCP). Patients treated with 0.05% urcosimod demonstrated not only a positive reduction in neuropathic corneal pain, but also favorable changes in corneal nerve structure which were not observed in the placebo group.